Merck & Co., Inc.
New York Stock Exchange•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.Company Description
- CEO
- Mr. Robert M. Davis J.D.
- Full Time Employees
- 70,000
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Address
- 2000 Galloping Hill Road Kenilworth NJ United States of America 07033
- IPO Date
- Invalid Date
- CIK
- 0000310158
- Website
- www.merck.com
- Business
- Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Company News
Daiichi Sankyo and Merck's cancer drug meets main goal in late-stage trial
Buy 9 Sustainable Dividend Dogs From Barron's August 100
Ten-Year Data for Merck's KEYTRUDA® (pembrolizumab) Demonstrates Sustained Overall Survival Benefit Versus Ipilimumab in Advanced Melanoma
KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Combination With Transarterial Chemoembolization Significantly Improved Progression-Free Survival Compared to TACE Alone in Patients With Unresectable, Non-Metastatic Hepatocellular Carcinoma
Where Will Merck Stock Be in 5 Years?
KEYTRUDA® (pembrolizumab) Plus Trastuzumab and Chemotherapy Significantly Improved Overall Survival (OS) Versus Trastuzumab and Chemotherapy Alone in First-Line Treatment of Patients With HER2-Positive Advanced Gastric or GEJ Adenocarcinoma
Merck Appears Ready To Return To June Highs (Technical Analysis)
Merck (MRK) Increases Yet Falls Behind Market: What Investors Need to Know
Here's Why Merck (MRK) Gained But Lagged the Market Today
MRK Stock Dips After SMMT's Cancer Drug Outshines Keytruda in Study
Merck (MRK) is a Top Dividend Stock Right Now: Should You Buy?
Summit Therapeutics' stock pops as lung-cancer treatment beats Merck blockbuster in late-stage trial
Summit Therapeutics' Lung Cancer Candidate Surpasses Merck's Multi-Billion Dollar Keytruda, Cuts Risk Of Disease Or Death By Half
Merck Stock Falls After Rival Beats Keytruda Cancer Drug in Trial
3 No-Brainer Dividend Stocks to Buy in September
5 Relatively Secure And Cheap Dividend Stocks To Invest In -- September 2024
Is Merck Stock Undervalued After Its Colossal Earnings Growth?
Buy 3 September Dogs Of The Dow; Watch 6
Merck & Co., Inc. (MRK) CEO Rob Davis presents at Morgan Stanley 22nd Annual Global Healthcare Conference (Transcript)
Why Did Merck Stock Rise 65%?